<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ado-trastuzumab emtansine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ado-trastuzumab emtansine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ado-trastuzumab emtansine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="88727" href="/d/html/88727.html" rel="external">see "Ado-trastuzumab emtansine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F16248342"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious hepatotoxicity has been reported, including liver failure and death in patients treated with ado-trastuzumab emtansine. Monitor serum transaminases and bilirubin prior to initiation of ado-trastuzumab emtansine treatment and prior to each ado-trastuzumab emtansine dose. Reduce the dose or discontinue ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ado-trastuzumab emtansine administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment with ado-trastuzumab emtansine. Withhold treatment for a clinically significant decrease in left ventricular function.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16253283"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kadcyla</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871576"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kadcyla</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F16248345"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-HER2;</li>
<li>
                        Antineoplastic Agent, Antibody Drug Conjugate;</li>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F16255288"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Actively manage modifiable cardiac risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) before initiating treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27918725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27918725'])">Ref</a></span>). Do not substitute ado-trastuzumab emtansine (United States) or trastuzumab emtansine (Canada) for or with fam-trastuzumab deruxtecan, conventional trastuzumab, trastuzumab/hyaluronidase, or pertuzumab/trastuzumab/hyaluronidase; products are different and are <b>NOT</b> interchangeable.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e5e9f745-f7ca-4fd0-943e-8140b9956239">Breast cancer, early, HER2+, adjuvant therapy for residual disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, early, HER2+, adjuvant therapy for residual disease:</b> IV: 3.6 mg/kg every 3 weeks for a total of 14 cycles in the absence of disease recurrence or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30516102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30516102'])">Ref</a></span>); Maximum dose: 3.6 mg/kg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8149bc7-9f08-44a6-b6fa-92e0fe923497">Breast cancer, metastatic, HER2+</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic, HER2+: </b> IV: 3.6 mg/kg every 3 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28526536','lexi-content-ref-23020162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28526536','lexi-content-ref-23020162'])">Ref</a></span>); Maximum dose: 3.6 mg/kg.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed or delayed doses:</i> If a planned dose is missed or delayed, administer as soon as possible (at the dose and rate most recently tolerated), do not wait until the next planned cycle. Then adjust schedule to maintain a 3-week interval between doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991908"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989195"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i> Refer to dosage adjustment for toxicity for dose level reductions:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early breast cancer:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grades 2 to 3 ALT elevations (&gt;3 to ≤20 times ULN on the day of scheduled treatment): Withhold until ALT recovers to ≤ grade 1, then resume with one dose level reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 AST elevations (&gt;3 to ≤5 times ULN on the day of scheduled treatment): Withhold until AST recovers to ≤ grade 1, then resume at the same dose level.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 AST elevations (&gt;5 to ≤20 times ULN on the day of scheduled treatment): Withhold until AST recovers to ≤ grade 1, then resume with one dose level reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 ALT or AST elevations (&gt;20 times ULN at any time): Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Hyperbilirubinemia:</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin &gt;1 to ≤2 times ULN on the day of scheduled treatment: Withhold until bilirubin recovers to ≤1 times ULN, then resume with one dose level reduction.</p>
<p style="text-indent:-2em;margin-left:8em;">Total bilirubin &gt;2 times ULN at any time: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic breast cancer:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 ALT, AST elevations (&gt;2.5 to ≤5 times ULN): Continue at same dose level.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 ALT, AST elevations (&gt;5 to ≤20 times ULN): Withhold until ALT, AST recover to ≤ grade 2, then resume with one dose level reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 ALT, AST elevations (&gt;20 times ULN): Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 hyperbilirubinemia (&gt;1.5 to ≤3 times ULN): Withhold until bilirubin recovers to ≤ grade 1, then resume at the same dose level.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 hyperbilirubinemia (&gt;3 to ≤10 times ULN): Withhold until bilirubin recovers to ≤ grade 1, then resume with one dose level reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 hyperbilirubinemia (&gt;10 times ULN): Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced liver injury: ALT, AST &gt;3 times ULN with concomitant total bilirubin &gt;2 times ULN: Permanently discontinue treatment (in the absence of another likely cause for the elevations [eg, metastases or concomitant medication]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nodular regenerative hyperplasia (all grades):</i> Early or metastatic breast cancer: Permanently discontinue treatment.</p></div>
<div class="block doo drugH1Div" id="F57490782"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>). <b>Note:</b> Per the manufacturer’s labeling, do not re-escalate ado-trastuzumab emtansine dose following a dose reduction.</p></div>
<div class="block dot drugH1Div" id="F16255290"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Ado-Trastuzumab Emtansine Dose Reduction Schedule for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Dose reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose level</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Starting dose</p></td>
<td align="left">
<p style="text-indent:0em;">3.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">First dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;">3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Second dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;">2.4 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Requirement for further dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue treatment</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<b>Note:</b> After a dose reduction is implemented, do not re-escalate dose.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Ado-Trastuzumab Emtansine Dose Modification for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Treatment modification</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Asymptomatic heart disease: Consider initiating heart failure medications (eg, angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker, and/or beta-blockers) in patients with asymptomatic (stage B) heart disease (ASCO [Armenian 2017], ESC (Lyon 2022]). For mild cardiac dysfunction, continue treatment with close cardiovascular monitoring; for moderate dysfunction, consider continuing treatment with close cardiovascular monitoring - initiation of heart failure medications is recommended; for severe dysfunction, interrupt treatment and utilize a multidisciplinary approach when deciding if/when to restart - initiation of heart failure medications is recommended (ESC [Lyon 2022]). Symptomatic heart disease: Initiate heart failure medications; for mild cardiac dysfunction, consider a multidisciplinary approach for decisions regarding treatment interruption versus continuation; for moderate or severe cardiac dysfunction, interrupt treatment and consider a multidisciplinary approach for decisions regarding treatment reinitiation (ESC [Lyon 2022]).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Early breast cancer:</i> Grades 2 to 3 thrombocytopenia on scheduled day of treatment (platelets 25,000/mm<sup>3</sup> to &lt;75,000/mm<sup>3</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment until platelet count recovers to ≤ grade 1 (platelets ≥75,000/mm<sup>3</sup>), then resume treatment at the same dose level. If 2 dosage delays are required, consider reducing by 1 dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Metastatic breast cancer:</i> Grade 3 thrombocytopenia (platelets 25,000/mm<sup>3</sup> to &lt;50,000/mm<sup>3</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment until platelet count recovers to ≤ grade 1 (platelets ≥75,000/mm<sup>3</sup>), then resume treatment at the same dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4 (platelets &lt;25,000/mm<sup>3</sup>) at any time</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment until platelet count recovers to ≤ grade 1 (platelets ≥75,000/mm<sup>3</sup>), then resume treatment with 1 dose level reduction.</p></td></tr>
<tr>
<td align="left" rowspan="5">
<p style="text-indent:0em;">Cardiotoxicity<sup>a</sup>: <i>Early breast cancer</i></p></td>
<td align="left">
<p style="text-indent:0em;">Left ventricular ejection fraction (LVEF) ≥50%</p></td>
<td align="left">
<p style="text-indent:0em;">Continue treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">LVEF 45% to &lt;50% and decrease is &lt;10% points from baseline</p></td>
<td align="left">
<p style="text-indent:0em;">Continue treatment and repeat LVEF assessment within 3 weeks.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">LVEF 45% to &lt;50% and decrease is ≥10% points from baseline</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF remains &lt;50% and has not recovered to &lt;10% points from baseline, discontinue treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">LVEF &lt;45%</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF &lt;45% is confirmed, discontinue treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Symptomatic heart failure, grade 3 to 4 left ventricular systolic dysfunction, grade 3 to 4 heart failure, or grade 2 heart failure with LVEF &lt;45%</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue treatment.</p></td></tr>
<tr>
<td align="left" rowspan="5">
<p style="text-indent:0em;">Cardiotoxicity<sup>a</sup>: <i>Metastatic breast cancer</i></p></td>
<td align="left">
<p style="text-indent:0em;">LVEF &gt;45%</p></td>
<td align="left">
<p style="text-indent:0em;">Continue treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">LVEF 40% to ≤45% and decrease is &lt;10% points from baseline</p></td>
<td align="left">
<p style="text-indent:0em;">Continue treatment and repeat LVEF assessment within 3 weeks.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">LVEF 40% to ≤45% and decrease is ≥10% points from baseline</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF has not recovered to within 10% points from baseline, discontinue treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">LVEF &lt;40%</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold treatment and repeat LVEF assessment within 3 weeks; if repeat LVEF &lt;40% is confirmed, discontinue treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Symptomatic heart failure</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue treatment.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Infusion-related reaction/hypersensitivity</p></td>
<td align="left">
<p style="text-indent:0em;">Any</p></td>
<td align="left">
<p style="text-indent:0em;">If reaction occurs, decrease infusion rate. Medications for the treatment of reactions should be available for immediate use.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Severe</p></td>
<td align="left">
<p style="text-indent:0em;">Interrupt infusion; permanently discontinue for life-threatening reactions.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Peripheral neuropathy</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Temporarily discontinue until resolves to ≤ grade 2.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Pulmonary toxicity</p></td>
<td align="left">
<p style="text-indent:0em;">Interstitial lung disease or pneumonitis</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Radiation therapy-related pneumonitis (adjuvant setting)</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue ado-trastuzumab emtansine if not resolving with standard treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue treatment.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F16255289"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F16328019"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11% to 19%), constipation (17% to 27%), diarrhea (12% to 24%; grades 3/4: ≤2%), nausea (40% to 42%; grades 3/4: &lt;1%), stomatitis (14% to 15%; grades 3/4: &lt;1%), vomiting (15% to 19%; grades 3/4: &lt;1%), xerostomia (14% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (10% to 14%; grades 3/4: 1% to 4%), hemorrhage (29% to 32%; grades 3/4: ≤2%), thrombocytopenia (29% to 31%; grades 3/4: 6% to 15%; including patients of Asian descent: grades 3/4: 19% to 45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (55% to 82%), increased serum aspartate aminotransferase (79% to 98%), increased serum bilirubin (7% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤18%), fatigue (36% to 50%), headache (28%), insomnia (12% to 14%), peripheral neuropathy (21% to 28%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (19% to 26%), musculoskeletal pain (30% to 36%), myalgia (14% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (14% to 18%), dyspnea (8% to 12%), epistaxis (22% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5% to 6%), left ventricular dysfunction (2% to 3%), peripheral edema (4% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (7% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (8%), dyspepsia (4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (9% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (5% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2% to 3%), infusion-related reaction (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (4% to 6%; neutralizing: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (5% to 8%), dizziness (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4% to 5%), conjunctivitis (4%), dry eye syndrome (4% to 5%), increased lacrimation (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (1%), radiation pneumonitis (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Portal hypertension (including nodular regenerative hyperplasia)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic encephalopathy, hepatic failure, hepatotoxicity (including severe hepatoxicity)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, interstitial pulmonary disease</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased left ventricular ejection fraction, heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor lysis syndrome</p></div>
<div class="block coi drugH1Div" id="F16255125"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i> There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to trastuzumab emtansine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F16255126"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Thrombocytopenia may occur (nadir achieved by day 8; generally resolves to ≤ grade 1 by the next scheduled dose), including ≥ grade 3 thrombocytopenia. Rare cases of severe and prolonged (&gt;90 days) ≥ grade 3 thrombocytopenia have been reported; most patients received concurrent therapy with recombinant human thrombopoietin. The incidence of thrombocytopenia was higher in patients of Asian ancestry. Has not been studied in patients with platelets &lt;100,000/mm<sup>3</sup> prior to treatment initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiotoxicity: May result in left ventricular ejection fraction (LVEF) reductions. Serious cases of heart failure have been observed. Ado-trastuzumab emtansine use has not been studied in patients with LVEF &lt;50%, with a history of symptomatic CHF, serious arrhythmia, or recent history (within 6 months) of myocardial infarction, or unstable angina.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation reactions: Irritant with vesicant-like properties; avoid extravasation. Local reactions (erythema, irritation, pain, swelling, or tenderness) secondary to extravasation have been noted. These were generally mild and typically occurred within 24 hours of infusion. There is a case report of skin necrosis (delayed) following extravasation (Shafaee 2017). Monitor infusion site during infusion for possible infiltration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Hemorrhagic events, including central nervous system, respiratory, and gastrointestinal hemorrhage, have been observed; some hemorrhages were fatal. Some events occurred in patients who were receiving anticoagulation or antiplatelet therapy, or in patients with thrombocytopenia, although bleeding also occurred in patients without additional risk factors. Use caution when administering with antiplatelet agents or anticoagulants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious hepatotoxicity, including liver failure and death, has been reported. Hepatotoxicity is typically manifested by asymptomatic and transient increases in transaminases, although fatal cases of severe drug-induced liver injury and associated hepatic encephalopathy have occurred; may be confounded by comorbidities or concomitant hepatotoxic medications. All fatal cases occurred in patients with metastatic breast cancer. Use with caution in patients with known active hepatic disease (eg, hepatitis B or C virus). Cases of nodular regenerative hyperplasia (NRH), a rare liver disorder characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been observed (by biopsy). NRH may lead to noncirrhotic portal hypertension. Consider NRH in patients with clinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on liver CT scan, although without associated transaminase elevations or other manifestations of cirrhosis. Diagnosis of NRH is confirmed only by histopathology.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/infusion-related reactions: Infusion reactions (flushing, chills, fever, bronchospasm, dyspnea, wheezing, hypotension, and/or tachycardia) have been reported. After termination of infusion, these reactions generally resolved within several hours to a day. Medications for the treatment of reactions should be available for immediate use. Serious allergic/anaphylactic reaction was observed (rare). Use is not recommended in patients who had trastuzumab permanently discontinued due to infusion reaction or hypersensitivity (has not been evaluated).</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Sensory peripheral neuropathy has been reported, usually grade 1, although grade 3 or higher peripheral neuropathy was also described. In the adjuvant setting, sensory and motor neuropathy were observed, with nearly one-third of cases not yet resolved at study analysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Interstitial lung disease, including pneumonitis has been reported; some cases resulted in acute respiratory distress syndrome and/or fatalities. Grade 3 pneumonitis has occurred. Signs and symptoms of pneumonitis include dyspnea, cough, fatigue, and pulmonary infiltrates. Radiation pneumonitis has been reported, including grade 3 toxicity. Patients with dyspnea at rest due to complications of advanced malignancy, comorbidities, or concurrent pulmonary radiation therapy may be at increased risk for pulmonary toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asian ancestry: The incidence of thrombocytopenia was higher in patients of Asian ancestry.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Do not interchange: Ado-trastuzumab emtansine and conventional trastuzumab are NOT interchangeable. Do not substitute. Ado-trastuzumab emtansine is also not interchangeable with fam-trastuzumab deruxtecan, trastuzumab/hyaluronidase, or pertuzumab/trastuzumab/hyaluronidase. Dosing and treatment schedules between ado-trastuzumab emtansine (Kadcyla) and fam-trastuzumab deruxtecan (Enhertu), conventional trastuzumab (Herceptin or trastuzumab biosimilars), trastuzumab/hyaluronidase (Herceptin Hylecta), or pertuzumab/trastuzumab/hyaluronidase (Phesgo) are different; confusion between the products may potentially cause harm to the patient. In Canada, the generic name for Kadcyla is trastuzumab emtansine (without the Ado- prefix) and may be confused with conventional trastuzumab. Verify product label prior to reconstitution and administration to prevent medication errors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human epidermal growth factor receptor 2 expression: Patients should be selected for therapy based on an approved companion diagnostic test for human epidermal growth factor receptor 2 (HER2) protein overexpression or HER2 gene amplification in tumor specimens. HER2 testing should be conducted using tests specific for breast cancers and by labs with demonstrated proficiency. Information on approved tests for HER2 testing is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=88427" target="_blank">http://www.fda.gov/CompanionDiagnostics</a>. Improper assay performance (including sub-optimally fixed tissue), failure to use specific reagents, deviation form assay instructions, and failure to include appropriate assay validation controls may lead to unreliable results.</p></div>
<div class="block foc drugH1Div" id="F16253284"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kadcyla: 100 mg (1 ea); 160 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F16255120"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570472"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Kadcyla Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $4,670.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $7,472.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871577"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kadcyla: 160 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kadcyla: 20 mg/mL (5 mL, 8 mL) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block adm drugH1Div" id="F16255361"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over 90 minutes (first infusion) or over 30 minutes (subsequent infusions if prior infusions were well tolerated) through a 0.2- or 0.22-micron inline polyethersulfone filter. Do not administer IV push or bolus. Do not administer with other medications.</p>
<p style="text-indent:0em;margin-top:2em;">Monitor patient during infusion for signs of infusion-related reactions (eg, fever, chills); monitor for at least 90 minutes following initial infusion and (if tolerated) for at least 30 minutes following subsequent infusions.</p>
<p style="text-indent:0em;margin-top:2em;">Check label to ensure appropriate product is being administered (ado-trastuzumab emtansine [United States] or trastuzumab emtansine [Canada] and fam-trastuzumab deruxtecan, conventional trastuzumab, trastuzumab/hyaluronidase, or pertuzumab/trastuzumab/hyaluronidase are different products and are <b>NOT </b>interchangeable).</p>
<p style="text-indent:0em;margin-top:2em;">Irritant with vesicant-like properties; avoid extravasation. Ensure proper needle or catheter position prior to administration. Closely monitor infusion site during administration.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>
<div class="block hazard drugH1Div" id="F49104395"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F16248201"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, early:</b> Adjuvant treatment (single agent) of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in patients with residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic:</b> Treatment (single agent) of HER2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination, and have either received prior therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Patients should be selected for therapy based on an approved companion diagnostic test for HER2 protein overexpression or HER2 gene amplification in tumor specimens.</p></div>
<div class="block mst drugH1Div" id="F16255118"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ado-trastuzumab emtansine may be confused with fam-trastuzumab deruxtecan, pertuzumab, pertuzumab/trastuzumab/hyaluronidase, trastuzumab, trastuzumab/hyaluronidase.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">In the United States, ado-trastuzumab emtansine (Kadcyla) may be confused with fam-trastuzumab deruxtecan, conventional trastuzumab (Herceptin), trastuzumab/hyaluronidase (Herceptin Hylecta), or pertuzumab/trastuzumab/hyaluronidase (Phesgo); products are <b>not</b> interchangeable.</p>
<p style="text-indent:-2em;margin-left:4em;">In Canada, trastuzumab emtansine (Kadcyla) may be confused with conventional trastuzumab (Herceptin); products are <b>not </b>interchangeable.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16369049"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F16369047"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthracyclines: Ado-Trastuzumab Emtansine may enhance the cardiotoxic effect of Anthracyclines.  Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component. Management: Avoid concomitant use of ado-trastuzumab emtansine and strong CYP3A4 inhibitors when possible. Consider alternatives that do not inhibit CYP3A4 or consider administering after CYP3A4 inhibitor discontinuation. Monitor for toxicities if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49042599"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: </b>
<b> Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception<b>.</b></b></p>
<p style="text-indent:0em;margin-top:2em;">Evaluate pregnancy status prior to treatment in patients who could become pregnant; effective contraception should be used during therapy and for 7 months after the last dose of ado-trastuzumab emtansine. Patients with partners who could become pregnant should use effective contraception during therapy and for 4 months after the last dose.</p></div>
<div class="block pri drugH1Div" id="F16255122"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]:</b>
<b>Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks.</b></p>
<p style="text-indent:0em;margin-top:2em;">Oligohydramnios and oligohydramnios sequence (manifested as pulmonary hypoplasia, skeletal malformations, and neonatal death) were observed following trastuzumab exposure during pregnancy (trastuzumab is the antibody component of ado-trastuzumab emtansine). Monitor for oligohydramnios if trastuzumab exposure occurs during pregnancy or within 7 months prior to conception; conduct appropriate fetal testing if oligohydramnios occurs. Based on the mechanism of action, the DM1 component of the ado-trastuzumab emtansine formulation may also cause fetal harm if administered during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">European Society for Medical Oncology guidelines for cancer during pregnancy recommend delaying treatment with HER-2 targeted agents until after delivery in pregnant patients with HER-2 positive disease (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ado-trastuzumab emtansine is ongoing. If ado-trastuzumab emtansine exposure occurs during pregnancy or within 7 months prior to conception, healthcare providers should report the exposure to the Genentech (888-835-2555).</p></div>
<div class="block brc drugH1Div" id="F16255124"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ado-trastuzumab emtansine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Endogenous immunoglobulins are found in breast milk. Based on the mechanism of action, the DM1 component of the ado-trastuzumab emtansine formulation may cause serious adverse reactions in a breastfed infant. The manufacturer does not recommend breastfeeding during treatment and for 7 months following the last dose of ado-trastuzumab emtansine.</p></div>
<div class="block mop drugH1Div" id="F16255365"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HER2 expression status; platelet count (at baseline and prior to each dose), transaminases and bilirubin (at baseline and prior to each dose). Verify pregnancy status (prior to treatment initiation in patients who could become pregnant). Evaluate left ventricular function (prior to and at least every 3 months during treatment; more frequently for decreased left ventricular ejection fraction). Monitor infusion site during infusion for possible infiltration; monitor closely for infusion reactions during infusion (especially with the initial infusion) and for 90 minutes after initial infusion and for 30 minutes after subsequent infusions. Monitor for signs and symptoms of bleeding (monitor closely if at bleeding risk due to thrombocytopenia and/or with concomitant anticoagulant or antiplatelet agents), neurotoxicity, including peripheral neuropathy, and/or pulmonary toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring (guideline recommendations): </i>Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017], ESC [Lyon 2022])<i>.</i> Obtain a baseline echocardiography (transthoracic preferred) and repeat every 3 months during treatment (may reduce to every 4 to 6 months if normal and asymptomatic), assess more frequently if clinically indicated and obtain echocardiography within 12 months after completion; in high- and very high-risk patients, assess troponin and natriuretic peptide at baseline and consider assessing every 2 to 3 cycles, and at 3 and 12 months after completion of therapy; in low- and moderate-risk patients, consider troponin and natriuretic peptide at baseline (post-anthracycline), every 3 months and 12 months after completion of therapy (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F16255182"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ado-trastuzumab emtansine is a HER2-antibody drug conjugate which incorporates the HER2 targeted actions of trastuzumab with the microtubule inhibitor DM1 (a maytansine derivative). The conjugate, which is linked via a stable thioether linker, allows for selective delivery into HER2 overexpressing cells, resulting in cell cycle arrest and apoptosis. </p></div>
<div class="block phk drugH1Div" id="F16255198"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.13 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: DM1: 93%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: DM1 undergoes hepatic metabolism via CYP3A4/5</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~4 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:  Near the end of the infusion</p></div>
<div class="block phksp drugH1Div" id="F51219901"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">Hepatic function impairment: Systemic exposure (AUC) was ~38% and ~67% lower in patients with mild (Child-Pugh class A) and moderate (Child-Pugh class B) impairment, respectively, compared to patients with normal hepatic function during cycles 1 and 2 of a 3.6 mg/kg ado-trastuzumab dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F28018949"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ujvira</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Kadcyla</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172893">
<a name="21172893"></a>Burris HA 3rd, Rugo HS, Vukelja SJ, et al, “Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy,” <i>J Clin Oncol</i>, 2011, 29(4):398-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/21172893/pubmed" id="21172893" target="_blank">21172893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28526536">
<a name="28526536"></a>Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [published corrections appear in <i>Lancet Oncol</i>. 2017;18(8):e433; <i>Lancet Oncol</i>. 2018;19(12):e667]. <i>Lancet Oncol</i>. 2017;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/28526536/pubmed" id="28526536" target="_blank">28526536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22271209">
<a name="22271209"></a>Girish S, Gupta M, Wang B, et al, “Clinical Pharmacology of Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate in Development for the Treatment of HER2-Positive Cancer,” <i>Cancer Chemother Pharmacol</i>, 2012, 69(5):1229-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/22271209/pubmed" id="22271209" target="_blank">22271209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799465">
<a name="24799465"></a>Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients With advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(19):2078-2099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/24799465/pubmed" id="24799465" target="_blank">24799465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23382472">
<a name="23382472"></a>Hurvitz SA, Dirix L, Kocsis J, et al, “Phase II Randomized Study of Trastuzumab Emtansine versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 2013, 31(9):1157-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/23382472/pubmed" id="23382472" target="_blank">23382472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. Published online July 27, 2020. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Genentech.1">
<a name="Genentech.1"></a>Kadcyla (ado-trastuzumab) [prescribing information]. South San Francisco, CA: Genentech Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kadcyla.2">
<a name="Kadcyla.2"></a>Kadcyla (ado-trastuzumab) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22649126">
<a name="22649126"></a>Krop IE, LoRusso P, Miller KD, et al, “A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine,” <i>J Clin Oncol</i>, 2012, 30(26):3234-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/22649126/pubmed" id="22649126" target="_blank">22649126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(Suppl 6):vi160-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799487">
<a name="24799487"></a>Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(19):2078-2099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/24799487/pubmed" id="24799487" target="_blank">24799487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28678590">
<a name="28678590"></a>Shafaee MN, Salahudeen AA, and Valero V. Skin necrosis after ado-trastuzumab emtansine extravasation. <i>J Oncol Pract.</i> 2017;13(8):555-556. DOI: 10.1200/JOP.2016.020198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/28678590/pubmed" id="28678590" target="_blank">28678590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23020162">
<a name="23020162"></a>Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer [published correction appears in <i>N Engl J Med</i>. 2013;368(25):2442]. <i>N Engl J Med.</i> 2012;367(19):1783-1791. doi: 10.1056/NEJMoa1209124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/23020162/pubmed" id="23020162" target="_blank">23020162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30516102">
<a name="30516102"></a>von Minckwitz G, Huang CS, Mano MS, et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. <i>N Engl J Med</i>. 2019;380(7):617-628. doi: 10.1056/NEJMoa1814017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/30516102/pubmed" id="30516102" target="_blank">30516102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222194">
<a name="24222194"></a>Welslau M, Diéras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. <i>Cancer</i>. 2014;120(5):642-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/24222194/pubmed" id="24222194" target="_blank">24222194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24101045">
<a name="24101045"></a>Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(31):3997-4013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ado-trastuzumab-emtansine-drug-information/abstract-text/24101045/pubmed" id="24101045" target="_blank">24101045</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 88427 Version 241.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
